<SEC-DOCUMENT>0001193125-16-724610.txt : 20160929
<SEC-HEADER>0001193125-16-724610.hdr.sgml : 20160929
<ACCEPTANCE-DATETIME>20160929080055
ACCESSION NUMBER:		0001193125-16-724610
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20160928
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160929
DATE AS OF CHANGE:		20160929

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21898
		FILM NUMBER:		161908331

	BUSINESS ADDRESS:	
		STREET 1:		225 SOUTH LAKE AVENUE
		STREET 2:		SUITE 1050
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101
		BUSINESS PHONE:		626-304-3400

	MAIL ADDRESS:	
		STREET 1:		225 SOUTH LAKE AVENUE
		STREET 2:		SUITE 1050
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d449184d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION 13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): September&nbsp;28, 2016 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Arrowhead Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>0-21898
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission File Number) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>46-0408024</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>225 South Lake Avenue, Suite 1050, Pasadena, CA 91101 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code (626)&nbsp;304-3400 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4 (c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;1.01 Entry into a Material Definitive Agreement. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Collaboration and License Agreements and Common Stock Purchase Agreement </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;28, 2016, Arrowhead Pharmaceuticals, Inc., a Delaware corporation (the &#147;Company&#148;), entered into two Collaboration and License
agreements, and a Common Stock Purchase Agreement with Amgen Inc., a Delaware corporation (&#147;Amgen&#148;). Under one of the license agreements, Amgen will receive a worldwide, exclusive license to Arrowhead&#146;s novel, RNAi ARC-LPA program.
These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the other agreement, Amgen will receive an option to a worldwide,
exclusive license for an RNAi therapy for an undisclosed genetically validated cardiovascular target. In both agreements, Amgen will be wholly responsible for clinical development and commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Common Stock Purchase Agreement, the Company will initially sell 3,002,793 shares of common stock (the &#147;Shares&#148;) to Amgen at a price of
$7.16 per share, which represents the 30-day volume-weighted average price of the common stock on the NASDAQ stock market over the 30 trading days preceding execution. These shares will be delivered in two closings per the terms of the agreement.
The second of these closings is subject to Hart-Scott-Rodino clearance. Subject to Amgen&#146;s exercise of the option, as defined in the collaboration agreement containing an option, Amgen has agreed to purchase, and the Company has agreed to sell,
an additional $5 million shares of common stock based on a 30 trading day formula surrounding the date of the option exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the
agreements taken together, Arrowhead will receive $35 million in upfront payments, $21.5 million in the form of an equity investment by Amgen in Arrowhead common stock, and up to $617 million in option payments, and development, regulatory and sales
milestone payments. Arrowhead is further eligible to receive single-digit royalties for sales of products against the undisclosed target and up to low double-digit royalties for sales of products under the ARC-LPA agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;3.02 Unregistered Sales of Equity Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The disclosure set forth above under Item&nbsp;1.01 is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Shares will be issued in a private placement transaction that is exempt from registration under Section&nbsp;4(a)(2) of the Securities Act of 1933 (the
&#147;Securities Act&#148;). Subject to the terms of the Common Stock Purchase Agreement, the Company will be required to file a registration statement on Form S-3 for the resale of the Shares under the Securities Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)&nbsp;Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>Exhibit&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated September 29, 2016</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: September&nbsp;29, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">ARROWHEAD PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Kenneth Myszkowski</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Kenneth Myszkowski</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d449184dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g449184g74s22.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g449184g61e86.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><I>News Release </I></B></P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>AMGEN AND ARROWHEAD PHARMACEUTICALS
ANNOUNCE TWO CARDIOVASCULAR COLLABORATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Amgen to Receive Worldwide Exclusive License to Arrowhead&#146;s RNAi ARC-LPA Program
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Amgen Receives Exclusive License Option to RNAi Therapy for Undisclosed Cardiovascular Target </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Arrowhead to Receive $56.5 Million in Upfront Payments and Initial Equity Investment and up to an Additional $617 Million in Potential
Milestone and Equity Payments </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Arrowhead Will Hold a Webcast Today at 9 a.m. ET </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THOUSAND OAKS, Calif. and PASADENA, Calif. (Sept. 29, 2016) &#151; Amgen (NASDAQ: AMGN) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced two
license and collaboration agreements to develop and commercialize RNA interference (RNAi) therapies for cardiovascular disease. These are the first programs to utilize Arrowhead&#146;s proprietary subcutaneous RNAi delivery platform. RNAi molecules
may be designed to target and shut down specific gene products that contribute to various diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under one agreement, Amgen receives a worldwide,
exclusive license to Arrowhead&#146;s novel, RNAi ARC-LPA program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the
second agreement, Amgen receives an option to a worldwide, exclusive license for a RNAi therapy for an undisclosed genetically validated cardiovascular target. In both agreements, Amgen will be wholly responsible for clinical development and
commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreements taken together, Arrowhead will receive $35 million in upfront payments; $21.5 million in the form of
an equity investment by Amgen in Arrowhead common stock; and up to $617 million in option payments, and development, regulatory and sales milestone payments. Arrowhead is further eligible to receive single digit royalties for sales of products
against the undisclosed target and up to low double digit royalties for sales of products under the ARC-LPA agreement. Additional financial terms of the agreements are not disclosed. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AMGEN AND ARROWHEAD PHARMACEUTICALS ANNOUNCE TWO CARDIOVASCULAR COLLABORATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Arrowhead&#146;s expertise in RNAi makes them a valuable partner as we translate genetic discoveries
into potential therapies that can improve health outcomes for patients,&#148; said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. &#147;This collaboration builds upon our commitment to cardiovascular disease
with targets that we believe are uniquely suited for RNAi-based therapy.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We have made great advances to our proprietary subcutaneous RNAi
delivery vehicle and in RNAi trigger modification and stabilization that enable rapid development of new RNAi therapeutics across multiple disease areas,&#148; said Christopher Anzalone, Ph.D., president and chief executive officer at Arrowhead.
&#147;Our capabilities and platform technologies are becoming increasingly validated, so we feel that now is a great time to expand the reach of our technologies and partner with other companies to maximize the value of our assets. We are thrilled
to be working with Amgen, one of the world&#146;s leading biotechnology companies, on this collaboration. Amgen&#146;s extensive development, regulatory, and commercial expertise makes them an ideal partner, and we look forward to a long and
productive relationship.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The closing of the ARC-LPA transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of
1976, as amended, and is expected to close before the end of the fourth quarter of 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Arrowhead Conference Call and Webcast Details </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arrowhead will host a conference call today, Sept. 29, 2016, at 9 a.m. ET. Investors may access a live audio webcast on Arrowhead&#146;s website at
<U>http://ir.arrowheadpharma.com/events.cfm</U>. For analysts that wish to participate in the conference call, please dial <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">855-215-6159</FONT></FONT> or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">315-625-6887</FONT></FONT> and enter Conference ID&nbsp;88684368. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A replay of the
webcast will be available on the Arrowhead website approximately two hours after the conclusion of the call and will remain available for 90&nbsp;days. An audio replay will also be available approximately two hours after the conclusion of the call
and will be available for 3&nbsp;days. To access the audio replay, dial <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">404-537-3406</FONT></FONT> and enter Conference ID&nbsp;88684368. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ARC-LPA </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARC-LPA is designed to reduce production
of apolipoprotein A, a key component of lipoprotein(a), which has been genetically linked with increased risk of cardiovascular diseases, independent of cholesterol and LDL levels. ARC-LPA is Arrowhead&#146;s first drug candidate to use a
subcutaneously administered delivery construct. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Amgen Cardiovascular </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Building on more than three decades of experience in developing biotechnology medicines for patients with serious illnesses, Amgen is dedicated to addressing
important scientific questions to advance care and improve the lives of patients with cardiovascular disease, the leading cause of morbidity and mortality worldwide.<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> Amgen&#146;s research into
cardiovascular disease, and potential treatment options, is part of a growing competency at Amgen that utilizes human genetics to identify and validate certain drug targets. Through its own research and development efforts, as well as partnerships,
Amgen is building a robust cardiovascular portfolio consisting of several approved and investigational molecules in an effort to address a number of today&#146;s important unmet patient needs, such as high cholesterol and heart failure. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AMGEN AND ARROWHEAD PHARMACEUTICALS ANNOUNCE TWO CARDIOVASCULAR COLLABORATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Amgen </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amgen&nbsp;is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and
delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amgen&nbsp;focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically
improve people&#146;s lives. A biotechnology pioneer since 1980,&nbsp;Amgen&nbsp;has grown to be one of the world&#146;s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of
medicines with breakaway potential. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, visit <U>www.amgen.com</U> and follow us on <U>www.twitter.com/amgen</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Arrowhead Pharmaceuticals </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arrowhead
Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to
induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead&#146;s
RNAi-based therapeutics leverage this natural pathway of gene silencing. The company&#146;s pipeline includes ARC-520 and ARC-521 for chronic hepatitis&nbsp;B virus infection, ARC-AAT for liver disease associated with alpha-1 antitrypsin deficiency,
ARC-F12 for hereditary angioedema and thromboembolic disorders, ARC-LPA for cardiovascular disease, and ARC-HIF2 for renal cell carcinoma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more
information please visit <U>www.arrowheadpharma.com</U>, or follow us on Twitter <U>@ArrowheadPharma</U>. To be added to the Company&#146;s email list and receive news directly, please visit <U>http://ir.arrowheadpharma.com/alerts.cfm</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amgen Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This news release
contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of
revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and
outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen,
including its most recent annual report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and any subsequent periodic reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> and
<FONT STYLE="white-space:nowrap">Form&nbsp;8-K.</FONT> Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this
document as a result of new information, future events or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No forward-looking statement can be guaranteed and actual results may differ
materially from those Amgen projects. Discovery or identification of new product candidates or development of </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AMGEN AND ARROWHEAD PHARMACEUTICALS ANNOUNCE TWO CARDIOVASCULAR COLLABORATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 4
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or
development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human
body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in
the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product
candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as
Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products after they are on the market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amgen&#146;s results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and
regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In
addition, sales of Amgen&#146;s products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be
affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen&#146;s research, testing, pricing, marketing and other operations are subject
to extensive regulation by domestic and foreign government regulatory authorities. Amgen or others could identify safety, side effects or manufacturing problems with its products after they are on the market. Amgen&#146;s business may be impacted by
government investigations, litigation and product liability claims. In addition, Amgen&#146;s business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance
obligations in the corporate integrity agreement between it and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its
patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial
manufacturing activities at a few key manufacturing facilities and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate
development. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for
Amgen&#146;s products are supplied by sole third-party suppliers. The discovery of significant problems with a product similar to one of Amgen&#146;s products that implicate an entire class of products could have a material adverse effect on sales
of the affected products and on its business and results of operations. Amgen&#146;s efforts to acquire other companies or products and to integrate the operations of companies Amgen has acquired may not be successful. Amgen may not be able to
access the capital and credit markets on terms that are favorable to it, or at all. Amgen is increasingly dependent on information technology systems, infrastructure and data security. Amgen&#146;s stock price may be volatile and may be affected by
a number of events. Amgen&#146;s business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AMGEN AND ARROWHEAD PHARMACEUTICALS ANNOUNCE TWO CARDIOVASCULAR COLLABORATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 5
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The scientific information discussed in this news release related to Amgen&#146;s product candidates is
preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Arrowhead Safe Harbor Statement under the Private Securities Litigation Reform Act: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This news release contains forward-looking statements within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities Litigation Reform
Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors
and uncertainties, including the success of the Amgen collaboration, as well as actual amounts received under that collaboration. Arrowhead&#146;s most recent Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and subsequent
Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> discuss some of the important risk factors that may affect our business, results of operations and financial condition. Arrowhead assumes no obligation to update or revise
forward-looking statements to reflect new events or circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DYNAMIC POLYCONJUGATES</B> is a trademark of Arrowhead Pharmaceuticals, Inc.<B>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B># # # </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONTACT: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amgen </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kristen Davis, 805-447-3008 (media) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kristen Neese, 805-313-8267 (media) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arvind Sood, 805-447-1060
(investors) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Arrowhead Pharmaceuticals, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vince
Anzalone, CFA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">626-304-3400 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ir@arrowheadpharma.com</U>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investor Relations: </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Trout Group </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chad Rubin 646-378-2947 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ir@arrowheadpharma.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Media: </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Russo Partners </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matt Middleman, M.D. 212-845-4272 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>matt.middleman@russopartnersllc.com</U> </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP> World Health Organization. Cardiovascular diseases (CVDs) fact sheet.
<U>http://www.who.int/mediacentre/factsheets/fs317/en/</U>. Accessed August 2016. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g449184g61e86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g449184g61e86.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( #8 [P,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /?Z *]Y>VNGVS7%W.D,2]68XJH0E-VBB9245=G'WOQ,L(7*
MV=G-< ?Q,0@/]:]"&7S?Q.QR2QD5\**\/Q0A+ 3Z7(J^J2 _S JWESZ2)6-7
M5'2Z1XKTC6F$5M<;)S_RRE&UOP]?PKCJX:I2UDM#IIUX5-$RA=?$#1K2[FMI
M%N=\3E&Q&",@X]:UC@:LHJ2L9O%4XNS+NB^+-.UZ[>VLUF#HF\^8F!C./7WK
M*MA9T8\TBZ=>-1VB;M<QN% !0 4 % !0 4 % !0 4 % !0!%<7$-I"TUQ*L4
M2]6<X H D5@RAE(*D9!'>@!: "@ H * "@ H * (KBZ@LXO-N)DBCR!N<X&:
M )1TXH JZC?P:7I\U[<-B*)<GU/H!5TX.I)1B3.2A'F9XMKFNWFO7IGN7P@/
M[N('Y4'^/O7T5&C&C&T3QJE651W9EYQ6YD!XX/'UH U_"Z;_ !3I@ Z3J?RK
MGQ+M1EZ&M'^)$J:J_F:Q>N.C3N?_ !XUI25H17D3-WDSK?AC&3JM])V6$+^;
M?_6K@S%^Y%>9UX->\V>G5XQZ04 ,$L;.4612P[ \T .R,X!Z4 (715+,P"CN
M3Q0 H92 0P(/3GK0 GF)OV!UW_W<\T #R)&,NZJ/4G% "JP905((/0B@ !!Z
M'-  2!U.* %H Y[QL0?"5\ >R_\ H0I/8:W-BUD2.PMM[JN8UQDX[4Q%F@!&
M=47<S!1ZDXH %=77<C!AZ@YH 6@!BRQLY19%+#J >: '9!X!Z4 (\B1C+NJC
MU)Q0!S?CDAO##$$$>='R/K2>PT=(G^K7Z4Q' ?$V_98K+3U.%8F5QZXX']:]
M7+H:N9P8R6BB>=*I9@JC+$X '<UZVQYQZGI^CZ/X.TA+W4T66[;&6*[CN_NJ
M/ZU\[B\:WULCTXPIX>'-/<EM/$?A_P 22_V?<V>TR<()D&&]@1T-<5'%^][K
M:81KTJSY6C%A\.#P[XT69"6LHH)+E&;L ,8/T)%>V\1[:A9[W2,U1]E5OTW.
M"=B[LYZL237J)6T. ])^&-MML+^Z(_UDBH#]!G^M>1F,O>C$]+!*R;.\KRSN
M.8UZ:ZU/6[;0+6=K>-HS-<R(<-MZ8%+R&M!7\"Z.(O\ 1_/@G'W9UE.X'UHL
M%REX.6Z36M;CO9/,N$9%=O[V,C-"&S.\+:(NNVTPOW=K*WF<)$K$!G)Y)^G%
M)*X-V+?B>R&CQ:':Z6"A6X81!F)PQQ_4T/0$:/\ PCVE^'K9M782S7=JC2-*
M\AR[8[C\:=K"O<KZ;X977+9-3UZ66XFN!O6(.52-3T  HL%[;$=]8-X.G@U#
M3II?[/:01W%L[%@ ?XA1L/<N::?[*\8WECG%O?I]IA]-W\0HV8NAG>+$N=;U
M@Z?9N5^P0-</CN_8?Y]:3&M#H+37(I/"JZNYX6'<X_VAP1^=.^@K:G,S6<EO
M\-[NYN,FXO&$\A/NPQ^E+H/J:=CX0M+^RBNM8>6ZNI4!.7(6,8X"@>E.PKB^
M'9)-*U/5='EF>6VM%$L3.<E5(SBA: S-L(+/Q,SZGKFH*(F<B"T\\($4'N,]
M:6X]M@OHK/PM/#J.B7ZF#S MQ:^<'#*>X&:-@W-36IKG6-;@T*UN&@MS%Y]S
M(APQ7LH-,2T'2>!=)$7^B^?;7"\K.DIW ^M%@N9GAJZN-.;Q'<:@WF3VY!D/
M]X@'^=)#9:TSPVFNVJ:IKLDEQ-<#>D6\A(U/0 "G8+VV,KQ5H#:'8*UA/)_9
M\TJK) [;@K9R"*35@3N>AI]Q?I5$GF/Q-1AK5FY^Z8,#\&/^->UES_=M>9YF
M,7OHY'3Y4M]2M9I/N1RJS?0$5WS3<&D<D':2;/1OB'9SW%I9WD(,EO%N#[><
M9Q@_3BOB\5%V3['=C8MI26QQ6BV5QJ&KVT-JI+B16+#^  YR:XZ<7*22."E%
MSFE$[_X@:G%8Z*;=2/M5T/+'J$X+?R KZ; TW.I?HCU,5-1A;JSR:O=/*/4_
M"O\ Q+IM+TGI(;1[J4?[3,,?I7B8GWU*IYV^X]2A[KC#RN=I7G'8<IKK2:)X
MDMM=\II+-HO(N-HR4&>&_P ^E+8:[&A+XNT**V\X:A&XQPB<L?;%%PLS'\'7
M$MWK>N7$\1BDD9&,;=5!S@'\,4(;+?@,#^P9B.]S)_2A"8OBD ZSX=!_Y^_\
M*&"-O5K+^T=)NK/.#-&5!]#VIBV,+0O$MI;V4>G:K(+*^M5$;K+\H8#@$&DF
M-HJZWJ4/B::#1-*;SU,BO<3*/D10?6C<:T+_ (M@:WL[35K=<RZ=*'QZIT84
M,2$\'0O-:76KSKB74)2XSV0< ?SH0,YV[MKB+5I?"L:D6MU=+<*P[1GEA^GZ
M4O(?F=+XT58_!]XB@*JJH ]!N%-["6YMV7_'A;_]<U_E3$<Y:1K-XZUN)CP]
MJBG\0*74?0QM(M= L'DTO7[*"*\A8[9I1@2KG@YI:#UZ%ME\*S:G!8Z9H\%_
M*[?O&BX6-?4FC0-2YK#-H'B2#6C$SV,D/V><H,F/G@_3I3V$M58T)O%VA0VW
MG#4(Y./E2/EF]L47"S.?\/12ZR/$T5PAAENB,HW5,@X!_2DAO0T- \26EG9)
MI>K2"RO;0>6RR\!@.A!^E-,31E^,?$-MJ=DMIIQ,\,<BO-,H^1>< 9]<TFQI
M6.^3[B_2J).3^(&COJ&B+=0KNEM"6('4H>O]#^%=^!JJ%3E>S.3%4^:%UT/)
MJ]T\H[+P[X]ETNU6RU"!KFW081E/SJ/3GJ*\[$8%5'S0=F=E+%."Y9:HV)OB
M+I5K"W]G:;(9&[,JQKGWQ7-#+9)ZM(U>+A%>ZC@M4U2ZUB^>\NWW2-P .BCT
M'M7K4Z<:4>6)PSFYN[+GAK2UU+5 ]P=ME;#SKAST"CG'XUGB*GLX66[T1=&'
M/+79;G1>%-3;5?B!<7C# EC<(OHHQ@?D*Y,33]GAE'L=%"?/7<CTRO&/2$90
MRE6 (/!!H S);#1M-87CV=M"V\*'$0SDG Z#U-(9H);PQRO(D2+))]]@H!;Z
MGO3$$,$-LFR")(DSG"* ,T $D$,KQM)$CM&<H64$J?4>E $E %:[TZRO@/M=
MI#-CIO0'% #[:TM[./R[:".%/[J* * )'1)$9'4,C#!5AD$4 $<:11K'&BHB
MC 51@ 4 0R?9$N#*XB\^.,G=@%U3^>* %'V;4+-6*I-;RJ& 9<AAVX- ;$P
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M2[VWCO\ [7##=0"&Z(!Y+C(R.#@T#+=Q>ZCIJ:M;I=O<M!'%(DDB L@8D,<
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M[FME:Q']@L_^?2'_ +]BJYY=Q<L>P?8+/_GTA_[]BCGEW#ECV)U544*H"J.
M , 5!6Q4O;!;V2U=G*_9Y?,QC.[@C'ZT 65AB6,1K&H0=%"\"@!VU0Q;:,G@
MG'6@!BP1(,+$BC&.% H =L3"C:,+T&.E  8T(8%%PQR>.M "-%&[!GC5B!@$
MC.* !HHW"AHU8+TR,XH &BC=U=XU9E^Z2,D?2@ >&*1@SQHQ' )4'% "[%SG
M:,XQG';TH :T$3HJ-$C*O0%00* '-%&Y4NBL5Z9&<4  C1<;448&!@=!0 )'
9'$"(T5!G.%&* '4 % !0 4 % !0 4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g449184g74s22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g449184g74s22.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !) - # 2(  A$! Q$!_\0
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M!(\?HC;@P!Y&2.<9/K?_  0R_P"4A6B?]@?4?_10KY KZ_\ ^"&7_*0K1/\
ML#ZC_P"BA7S_ !#A*6%X>Q&'H*T8TY)+LK,^FX6QU;&<487%8AWG*K!M]W=:
MG[@T445_)1_;85_/C_P4A^/I_:0_;0\<>(8IS/IMO>G2M,.?E%M;?NE*^S,'
M?_@9K]T_VG-9\0Z#^SUXRN?"6F7FL>)QI-Q'I5I:X\V6Y="D9&2!\K,&//13
M7X9#_@E_^T'CGX5>*&/<GR>3_P!_*_8/"A8.A4KX[%58Q=E&/-))]Y;OT_$_
M#/&AX_$TL/E^#I3G&[G+EBVM-(K1>OX'?_\ !-O_ ();M^WUX2\3:W=^*[CP
MI8:%>16,#Q:<+O[9*R%Y!S(FW:#'ZYW^U?2W_$.!IO\ T5W4?_"=3_Y(KZH_
MX)6?LYZA^S'^Q;X:T+6]/ETOQ%?23ZIJMM+CS(9Y9#A&P2,K&L8Z]J^BZ\WB
M'Q$S99E6C@*]J2DU&RBU9:7NT[WWWZGJ\,>%N2/*:$LRPW-6<4Y7E-.[UM92
M25KVVZ'\X/[5WP-C_9I_:*\5^!(M2?6(_#5V+5;UX! UQF-'R4!8+]['4]*]
ML_X)^_\ )J7[4_\ V)EO_P"C9*['_@H=_P $_OC1\5/VU_B'XA\._#GQ!JVB
M:KJ2RVEY!Y7EW">3&N1EP>H/;M74?L4_L)_%_P !_L[_ +0VCZSX!UO3=2\5
M^%H;+2()S$#?S"1R40[\9P1UQ7ZEC<^PE?)*4JE>#J/V+?O1O?G@Y:7TZW['
MX]EW#6-P_$-94L--4E[=1]V5K<DU&SMK?1+N?GO_  ?A7[,>,?!2>//^""5O
M:-&)'MO =KJ$?'*O;[)P1_W[_6OSJ/\ P2G_ &AMO_)+=<Z?\][;_P".5^N/
MP[^"_B&S_P""6<'@.^TF>'Q0/ $VE-IS%#(+HVCHL6<[<[R!UQ[UXGB!G6#D
ML%4PU:,G"K&6DD[6ZZ,]_P ,<@QU-X^GBZ$X*=&45S1:O?HKK5GX& YK]DO^
M"$'@J+P_^P7K>K!,7'B#6[Z9VQR4BC2%1] 4;\S7YW1_\$J/VAQ&N?A;KG3_
M )[VW_QROUK_ ."8'P2\1_ O]@S0?#'B?29M'\0QF_DN+*4J9(S)/*4R5)&2
MI4]>XI^)F<X.ME"I8:M&3<XW49)Z)-]'M>PO"/A_'8?.Y5L70G!1IRLY1:5V
MXK=K>S9^"]Y_Q^S_ /75_P#T(U[MK_[+ESK7_!/?PQ\6])M&E72M?O\ 1=>9
M%R8XF:-K:8_[(9GC)_VTJY=?\$JOVA7NI2/A=KA#2,0?/MNA)_Z:5^G_ /P2
MA_9@UKX;?L+W_@3XF^%C92:IJM_]KTJ_"2K<6TRQK\P4D88!N^>*]OBGB_"X
M'#4L5A*L:CC.-XQDFW%II[/^G8^?X-X%QF88NMA,;1G3C*G*TI0DDI)Q<=6O
MO[JY^,GP3^-/B/\ 9Z^)^D^+_"E^VG:YHTOF0R8W)(I&&CD7^)'4E64]0?QK
M]8?V?/\ @OO\,/&WA^"/Q_8ZKX*UQ5"W#0VSWUA*V.6C9,R*"?X67C^\>M?-
M'[<?_!#SQG\)=<O-<^%5O<^,O"DKM(NF*X;5--!YV!3CST'0%?G]5/WC\-^)
MO">J^"M2>SUG2]2TB[C)5H+VU>WD4CKE7 -5BLNX?XLHQKJ5Y);Q=IKR:U_%
M/RW)P>9\3<%5YX=QM%O:2O"7FGI^#79['Z__ !__ ."^GPM\#^';A/ =GJWC
M77"I6W\RV>RL(V[-(\@#D#T5,GU'6OR=^./QO\2?M&?%'5?&'BR_;4=;U>3?
M*^-L<*#A(HU_AC48 7^9)-<_X>\-:EXMU!+32=.U#5+J0@+#9VSSR,3Z*H)K
M[0_8P_X(D?$/XXZU9ZI\0K:Z\ ^$58/+%. -5OEZ[(XN?*STW28([*:>#RO(
M.%*4J[ERR:WD[S:[)?HEZ[$X[-^)N-*T,,H<T4_ABK03[MN_WMZ=-SRO]FC]
ME6Z\3_LB_&;XM:G:,NC^&M'&F:.\BX%S>RW$(E=?411$J?\ :E'H:^=77>A'
MJ,5^^?[9O[,WV?\ X)R>*_AE\-/#@8QZ5#9:3I5H55I-MQ$YY8@%B S%F.2<
MDG)K\D/^'5'[0W_1+=<_[_VW_P <K#A3C+"X^.(Q.*JQIWG:,922:BHQMN^K
MNWYW.KC3@+&9;+"X3!4956J=YRC%M.;E*^RZ*R7DD?5W@'_@X5M/!/@71=&/
MPLN[@Z18061E&NJOF^7&J;L>2<9VYQ76?%K_ (*'Q?\ !0#_ ()I?'NZB\*S
M>%_^$7M]/A*R7XNOM'G7*-GA%VXV>^<U\2_\.J/VAO\ HENN?]_[;_XY7TU^
MR]^PC\7?!'_!/S]H;PGJO@;5++Q%XM&E_P!CV+RPF2_\J8M)M(<@;1SR17B9
MGD_"^%]GB\%*'M54INZJ7_Y>1YG;F:VO?33<^AR?/>,<8ZF!S"$_9.E55G2M
MK[*7*K\J=[VMKJ]#\XCTK]Q?V9?V?M+_ &H_^"0/@[P/JR)Y.M^%U2"9ADVE
MPK,T,P]TD"GW ([U^7I_X)4?M#$?\DMUS_O_ &W_ ,<K]G/V /A]K/PI_8R^
M'?AWQ#82Z7K>D:0EO>6DI4O!(&;*DJ2.XZ&LO$[.L/+!X>>!K1E.%127+)-J
MR=GH^YKX0</XJGC<33S'#RC3G2<7S1:3NU=:KL?SX>*_"U]X&\5:GHNJ0-;:
MEH]W+97<3#F.6-RCC\P:^K_^"&7_ "D*T3_L#ZC_ .BA7H'_  4Y_P""9_Q3
M\>?MJ>+O$7@+P-J6N>'_ !%Y&H"YMY8507#1*LPPS@Y\Q6;I_%6W_P $D?V#
M_B]\ _VT])\2>,/ VJ:%H<&F7L$EW/+"R*[QX485R>3[5]%G'$F QO#M6HJT
M%.=)OEYE>[CM:][WT/ELBX2S+ <54:;H3=.G62YN67+92WO:UK:W/UFHHHK^
M8#^O@(S1110 4444 &,4F*6B@ HZ444 %(!BEHH **** "JFJ:#8ZX@6]LK2
M\4=!/"L@'Y@U;HIIM.Z$TFK,IZ7X?L-#4BRLK2S!ZB"%8\_D!5S%%%#;;NP2
<25D%%%%(84F*6B@ HHHH *",T44 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
